Equivalence of the Color Trails Test and Trail Making Test in Nonnative English-Speakers

Dugbartey, Anthony T.

doi:10.1016/s0887-6177(99)00034-7

Cited by 23 publications

(26 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such differences have been noted previously[6] and are not surprising in this sample for a number of reasons. First, performance on Trails B is predicated on the notion that it draws upon over-learned serial stimuli[30]. In Russia, the alphabet is not overlearned, nor is it learned in the same manner as it is in the U.S., i.e.…”

Section: Discussionmentioning

confidence: 99%

“…The concept that speeded cognitive performance is as important as accurate cognitive performance is not as valued a cultural concept in certain cultures as it is in the U.S. [37]. In a comparison of 50 U.S. and 50 Russian participants' performance on timed tasks and attitudes toward testing, Agranovich et al[37] found that Russians performed slower on the Color Trails Test[29], which is similar to the Trail Making Test Part B[30] but thought to be more culturally fair. Participants completed an assessment of attitudes toward time, the Culture of Time Inventory-33 (COTI-33).…”

Section: Discussionmentioning

confidence: 99%

“…There is some debate over whether Trails B is a culturally fair test and alternatives have been developed, such as the Color Trails Test[29]. However, some have suggested that the alternative Color Trails Test is not an equivalent measure[30]. The CERAD WLM task was developed as part of the CERAD protocol for the assessment of dementia and has proven to be a sensitive test for mild impairment as well as dementia[26,31,32].…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

A comparison of neuropsychological performance between US and Russia: Preparing for a global clinical trial

Hayden

Makeeva²,

Newby

et al. 2014

Alzheimer's & Dementia

View full text Add to dashboard Cite

Background Understanding regional differences in cognitive performance is important for interpretation of data from large multinational clinical trials. Methods Data from Durham and Cabarrus Counties in North Carolina, U.S. and Tomsk, Russia (n=2,972) were evaluated. The Montreal Cognitive Assessment (MoCA), Trail Making Test Part B (Trails B), CERAD Word List Memory Test delayed recall (WLM), and self-report ADCS Mail-In Cognitive Function Screening Instrument (MCFSI) were administered at each site. Multilevel modeling measured the variance explained by site and predictors of cognitive performance. Results Site differences accounted for 11% of the variation on the MoCA; 1.6% on Trails B; 1.7% on WLM; and 0.8% in MCFSI scores. Prior memory testing was significantly associated with WLM. Diabetes and stroke were significantly associated with Trails B and MCFSI. Conclusions Sources of variation include cultural differences, health conditions, and exposure to test stimuli. Findings highlight the importance of local norms to interpret test performance.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

A comparison of neuropsychological performance between US and Russia: Preparing for a global clinical trial

Hayden

Makeeva²,

Newby

et al. 2014

Alzheimer's & Dementia

View full text Add to dashboard Cite

show abstract

“…RBANS yields a total score and sub-scores for five cognitive domains: immediate memory, delayed memory, attention, visual spatial and language, with higher scores reflecting better performance [17]. Other clinical outcomes included Color Trails Test [18], Clinical Global Impression of Change (CGIC) [19], Clinical Global Impression of Disease Severity (CGIds) [20] and the Geriatric Depression Screen (GDS) to assess mood [21]. …”

Section: Methodsmentioning

confidence: 99%

Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy

Tsai

Lobach

Bang

et al. 2016

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

Introduction There are no effective treatments for progressive supranuclear palsy (PSP). Volumetric MRI (vMRI) may be a useful surrogate outcome measure in PSP clinical trials. The goal of the study was to evaluate the potential of vMRI to correlate with clinical outcomes from an international clinical trial population. Methods PSP patients (n = 198) from the AL-108-231 trial who had high quality vMRI and Progressive Supranuclear Palsy Rating Scale (PSPRS), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Schwab and England Activities of Daily Living (SEADL), Color Trails Test, Geriatric Depression Screen (GDS) and one year Clinician Global Impression of Change (CGIC) data from the baseline and 52 week visits were included. Linear regression was used to relate baseline values and annual clinical rating scale changes to annual regional vMRI changes (whole brain, ventricular, midbrain and superior cerebellar peduncle volumes). Results Effect sizes (Cohen's d) measuring disease progression over one year were largest for vMRI (midbrain [1.27] and ventricular volume [1.31]) but similar to PSPRS (1.26). After multiple comparison adjustment, annual changes in PSPRS, RBANS, SEADL, Color Trails Test, GDS and one year CGIC were modestly correlated with annual vMRI changes (p < 0.05). Baseline neuropsychological status on RBANS (p = 0.019) and Color Trails (p < 0.01) predicted annual midbrain atrophy rates. Conclusion Standard vMRI measurements are sensitive to disease progression in large, multicenter PSP clinical trials, but are not well correlated with clinical changes. vMRI changes may be useful as supportive endpoints in PSP trials.

show abstract

“…Tests were designed for administration in Spanish or English (Dugbartey et al, 2000; Jacobs et al, 1995). The tests are described in the Appendix.…”

Section: Methodsmentioning

confidence: 99%

Predictors of Retest Effects in a Longitudinal Study of Cognitive Aging in a Diverse Community-Based Sample

Gross

Benitez

Shih

et al. 2015

J Int Neuropsychol Soc

View full text Add to dashboard Cite

OBJECTIVE Better performance due to repeated testing can bias long-term trajectories of cognitive aging and correlates of change. We examined whether retest effects differ as a function of individual differences pertinent to cognitive aging: race/ethnicity, age, sex, language, years of education, and dementia risk factors including APOE ε4 status, baseline cognitive performance, and cardiovascular risk. METHOD We used data from the Washington Heights-Inwood Columbia Aging Project, a community-based cohort of older adults (n=4,073). We modeled cognitive change and retest effects in summary factors for general cognitive performance, memory, executive functioning, and language using multilevel models. Retest effects were parameterized in two ways, as improvement between the first and subsequent testings, and as the square root of the number of prior testings. We evaluated whether the retest effect differed by individual characteristics. RESULTS The mean retest effect for general cognitive performance was 0.60 standard deviations (95%CI: 0.46, 0.74), and was similar for memory, executive functioning, and language. Retest effects were greater for participants in the lowest quartile of cognitive performance, consistent with regression to the mean. Retest did not differ by other characteristics. CONCLUSIONS Retest effects are large in this community-based sample, but do not vary by demographic or dementia-related characteristics. Differential retest effects may not limit the generalizability of inferences across different groups in longitudinal research.

show abstract

Equivalence of the Color Trails Test and Trail Making Test in Nonnative English-Speakers

Cited by 23 publications

References 30 publications

A comparison of neuropsychological performance between US and Russia: Preparing for a global clinical trial

A comparison of neuropsychological performance between US and Russia: Preparing for a global clinical trial

Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy

Predictors of Retest Effects in a Longitudinal Study of Cognitive Aging in a Diverse Community-Based Sample

Contact Info

Product

Resources

About